SS-31vsTesamorelin + Ipamorelin

SS-31 (elamipretide, D-Arg-Dmt-Lys-Phe-NH2) is a cell-permeable, mitochondria-targeted tetrapeptide with an alternating aromatic-cationic motif that drives its remarkable 1,000-fold concentration within mitochondria. This accumulation is driven by the highly negative mitochondrial membrane potential (-180 mV), which electrostatically attracts the cationic peptide, and by its lipophilic aromatic residues which partition into the inner mitochondrial membrane.

Once concentrated in the inner mitochondrial membrane, SS-31 selectively binds to cardiolipin — a unique dimeric phospholipid found almost exclusively in this membrane. Cardiolipin plays an essential structural role: it anchors cytochrome c to the inner membrane surface, optimizing electron transfer between Complex III and Complex IV of the electron transport chain (ETC). With aging and disease, cardiolipin undergoes peroxidation by reactive oxygen species (ROS), which disrupts its interaction with cytochrome c. Loosened cytochrome c transfers electrons less efficiently, increasing electron leak to molecular oxygen and generating more ROS — creating a vicious cycle of mitochondrial decline.

SS-31 breaks this cycle by stabilizing the cardiolipin-cytochrome c interaction, restoring optimal electron transfer efficiency and reducing ROS generation at the source. It also protects cardiolipin from peroxidation by ROS scavenging through its dimethyltyrosine (Dmt) residue. The downstream effects are profound: restored mitochondrial membrane potential, improved ATP production, reduced oxidative damage to mitochondrial DNA and proteins, and prevention of the mitochondrial permeability transition pore (mPTP) opening that triggers apoptosis. In aged tissues, where mitochondrial dysfunction is a hallmark of cellular decline, SS-31 effectively rejuvenates mitochondrial function toward a younger phenotype. Clinical studies have shown improvements in skeletal muscle energetics, cardiac function, and exercise tolerance in elderly subjects and patients with mitochondrial myopathy.

The Tesamorelin + Ipamorelin combination pairs the only FDA-approved GHRH analogue with the most selective growth hormone secretagogue, creating a dual-pathway approach similar in principle to CJC-1295/Ipamorelin but with tesamorelin's unique advantages for body composition.

Tesamorelin activates the GHRH receptor on pituitary somatotrophs through the Gs/cAMP/PKA pathway, stimulating GH gene transcription and secretion. Its trans-3-hexenoic acid modification at position 1 provides enhanced receptor affinity and modest DPP-IV resistance compared to native GHRH. Ipamorelin simultaneously activates the GHS-R1a receptor via the Gq/11/PLC/calcium pathway, providing the same synergistic amplification of GH pulses described for the CJC/Ipa combination.

The distinguishing advantage of tesamorelin in this stack is its clinically demonstrated effect on visceral adipose tissue (VAT). In multiple randomized controlled trials for HIV-associated lipodystrophy, tesamorelin reduced trunk fat by 15-18% over 6 months, with visceral fat reduction being proportionally greater than subcutaneous fat reduction. This preferential visceral fat mobilization occurs because visceral adipocytes express the highest density of GH receptors and are most responsive to GH-mediated hormone-sensitive lipase activation. The GH elevations produced by tesamorelin/ipamorelin combination may be greater than tesamorelin alone (due to the synergistic dual-pathway effect), potentially enhancing this visceral fat-targeting effect. The combination also benefits from tesamorelin's full-length GHRH sequence (44 amino acids vs 29 for CJC-1295), which may provide more complete receptor activation, and from the preserved pulsatility that both agents maintain through intact somatostatin feedback regulation.